Voices: FDA’s CDRH continued efforts to return to normal

CDRH has worked tirelessly to meet the unprecedented demands of COVID-19 and fulfill our mission of protecting public health.

If your email program has trouble displaying this email, view as a webpage. FDA's Center for Devices and Radiological Health's Continued Efforts to Return to Normal: Reopening for All Pre-Submissions Since the beginning of the COVID-19 pandemic, the demand for medical devices has far exceeded anything we have seen in previous public health emergencies. The U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) has worked to address these unprecedented demands, while continuing to fulfill our mission to protect public health and facilitate medical device innovation. However, the significant increase in workload has adversely impacted our premarket review times for both COVID and non-COVID medical devices and our ability to meet all requests for pre-submission meetings. Last year, we communicated about the steps we were taking to return our premarket program to normal operations. Today, we are providing an update. Read More Questions? If you have questions, contact the Division of Industry and Consumer Education.

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA